All Things Multiple Sclerosis Research HSCT as a Frontline Therapy to stop MS in its tracks for 80% of MS Fighters.
Check out HSCTHope on Facebook to ask questions and engage with people who have gone through the Therapy.
HSCTHope.org
What goes on inside our hospital pharmacy? 💊
Today we welcomed almost 80 people to our department in Craigavon Area Hospital to experience all things pharmacy - whether that be the role of an assistant, technician or clinical pharmacist.
pulse.ly/ithkwq11im
#TeamSHSCT
These results provide evidence for the clinical relevance of including genomic features into the transplantation decision making process, allowing personalizing the hazards and effectiveness of HSCT in patients with MDS. Journal of Clinical Oncology ASCO ESMO - Eur. Oncology OncoAlert @OncoDaily #Oncology
It’s MDS and HSCT week!!!🤩 off the press in Blood Journal 👉Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms? ashpublications.org/blood/article-…
◾️Specific anticancer treatment proven to have high risk of long term CV complications:
•Doxorubicin >250mg/m2
•RT>15 Gy MHD
•Both doxorubicin >100mg/m2 and RT 5-15 Gy MHD
•High-risk HSCT patients
#cardiooncology 🫀
Please help me raise any amount towards £40,000 for my daughter's HSCT treatment, which could halt the progression of her MS. The NHS has declined to offer her this treatment, opting instead to provide medication ! #bigpharmasucks
justgiving.com/crowdfunding/c…
Navitating the Transplant Journey: A Guide for Nurses.
Alhamdulillah.. setahun perjalanan penghasilan buku ni.
Semoga bermanfaat
#nurse #transplant #hsct #HappyNursesWeek
New publication out in ICB - the journal 🥳. We studied a cohort of pediatric recipients of allo #HSCT from HUS Helsingin yliopistollinen sairaala over 2 yrs after the transplantation. We used Olink Proteomics to look for soluble biomarkers of inflammation, tiny🧵 onlinelibrary.wiley.com/doi/10.1111/im…
📢 #Allogeneic #Mesenchymal cells can be useful in the treatment of patients with #complications post- #HSCT who are not responding to other #treatment options.
💡If interested, please read our latest paper:
🔗doi.org/10.3389/fped.2…
Is there still room for HSCT in the treatment of CML in the tyrosine kinase inhibotors era ? LABMT Young LABMT ASTCT ASTCT_Journal ASH ASH Clinical News